Oncolytic virus-initiated protective immunity against prostate cancer

Molecular Therapy

Volumn 19, Issue 4, 2011, Pages 797-804

  Gujar, Shashi A ^a   Pan, Da ^a   Marcato, Paola ^a   Garant, Katy A ^a   Lee, Patrick W K ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CD8 ANTIGEN; CXCL11 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYMPHOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCYTE CHEMOTACTIC PROTEIN 1; ONCOLYTIC VIRUS; PLATELET DERIVED GROWTH FACTOR BB; RANTES; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UROKINASE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL; CD8+ T LYMPHOCYTE; CELL HOMING; CONTROLLED STUDY; DENDRITIC CELL; DISEASE MODEL; GROWTH INHIBITION; IMMUNE RESPONSE; LYMPHOCYTE HOMING; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROSTATE CANCER; PROTEIN EXPRESSION; REOVIRUS; TUMOR IMMUNITY;

ORTHOREOVIRUS;

EID: 79953294511     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.297     Document Type: Article

References (47)

1. Jemal, A, Siegel, R, Ward, E, Hao, Y, Xu, J and Thun, MJ (2009). Cancer statistics 2009. CA Cancer J Clin 59: 225-249.
2. Fong, L and Small, EJ (2003). Immunotherapy for prostate cancer. Semin Oncol 30: 649-658. (Pubitemid 37296789)
3. Drake, CG (2009). Immunotherapy for prostate cancer: walk, don't run. J Clin Oncol 27: 4035-4037.
4. Drake, CG (2010). Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 10: 580-593.
5. Thirukkumaran, CM, Nodwell, MJ, Hirasawa, K, Shi, ZQ, Diaz, R, Luider, J et al. (2010). Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res 70: 2435-2444.
6. Vieweg, JW (2008). Prostate cancer: targeting complexity. Curr Opin Urol 18: 261-262. (Pubitemid 351489375)
7. McNeel, DG, Dunphy, EJ, Davies, JG, Frye, TP, Johnson, LE, Staab, MJ et al. (2009). Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 27: 4047-4054.
8. Kiessling, A, Füssel, S, Wehner, R, Bachmann, M, Wirth, MP, Rieber, EP et al. (2008). Advances in specific immunotherapy for prostate cancer. Eur Urol 53: 694-708.
9. Drake, CG and Antonarakis, ES (2010). Update: immunological strategies for prostate cancer. Curr Urol Rep 11: 202-207.
10. Antonarakis, ES and Drake, CG (2010). Current status of immunological therapies for prostate cancer. Curr Opin Urol 20: 241-246.
11. Marcato, P, Shmulevitz, M and Lee, PW (2005). Connecting reovirus oncolysis and Ras signaling. Cell Cycle 4: 556-559. (Pubitemid 41359780)
12. Coffey, MC, Strong, JE, Forsyth, PA and Lee, PW (1998). Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334. (Pubitemid 28524498)
13. Kelly, K, Nawrocki, S, Mita, A, Coffey, M, Giles, FJ and Mita, M (2009). Reovirus-based therapy for cancer. Expert Opin Biol Ther 9: 817-830.
14. Lal, R, Harris, D, Postel-Vinay, S and De Bono, J (2009). Reovirus: Rationale and clinical trial update. Curr Opin Mol Ther 11: 532-539.
15. Harrington, KJ, Vile, RG, Melcher, A, Chester, J and Pandha, HS (2010). Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev 21: 91-98.
16. Marcato, P, Shmulevitz, M, Pan, D, Stoltz, D and Lee, PW (2007). Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol Ther 15: 1522-1530. (Pubitemid 47099309)
17. Shmulevitz, M, Marcato, P and Lee, PW (2010). Activated Ras signaling significantly enhances reovirus replication and spread. Cancer Gene Ther 17: 69-70.
18. Shmulevitz, M, Marcato, P and Lee, PW (2005). Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer. Oncogene 24: 7720-7728. (Pubitemid 41670674)
19. Prestwich, RJ, Ilett, EJ, Errington, F, Diaz, RM, Steele, LP, Kottke, T et al. (2009). Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 15: 4374-4381.
20. Prestwich, RJ, Harrington, KJ, Vile, RG and Melcher, AA (2008). Immunotherapeutic potential of oncolytic virotherapy. Lancet Oncol 9: 610-612. (Pubitemid 351890246)
21. Errington, F, Steele, L, Prestwich, R, Harrington, KJ, Pandha, HS, Vidal, L et al. (2008). Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 180: 6018-6026.
22. Foster, BA, Gingrich, JR, Kwon, ED, Madias, C and Greenberg, NM (1997). Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57: 3325-3330. (Pubitemid 27355467)
23. Rabinovich, GA, Gabrilovich, D and Sotomayor, EM (2007). Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25: 267-296. (Pubitemid 46697910)
24. Galli, R, Starace, D, Busà, R, Angelini, DF, Paone, A, De Cesaris, P et al. (2010). TLR stimulation of prostate tumor cells induces chemokine-mediated recruitment of specific immune cell types. J Immunol 184: 6658-6669.
25. Younger, AR, Amria, S, Jeffrey, WA, Mahdy, AE, Goldstein, OG, Norris, JS et al. (2008). HLA class II antigen presentation by prostate cancer cells. Prostate Cancer Prostatic Dis 11: 334-341.
26. Sanda, MG, Restifo, NP, Walsh, JC, Kawakami, Y, Nelson, WG, Pardoll, DM et al. (1995). Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 87: 280-285.
27. Redmond, WL, Gough, MJ, Charbonneau, B, Ratliff, TL and Weinberg, AD (2007). Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. J Immunol 179: 7244-7253.
28. Gujar, SA, Marcato, P, Pan, D and Lee, PW (2010). Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity. Mol Cancer Ther 9: 2924-2933.
29. Sanderson, S and Shastri, N (1994). LacZ inducible, antigen/MHC-specific T cell hybrids. Int Immunol 6: 369-376. (Pubitemid 24087229)
30. Hogquist, KA, Jameson, SC, Heath, WR, Howard, JL, Bevan, MJ and Carbone, FR (1994). T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27. (Pubitemid 24035278)
31. Wang, X, Yu, J, Sreekumar, A, Varambally, S, Shen, R, Giacherio, D et al. (2005). Autoantibody signatures in prostate cancer. N Engl J Med 353: 1224-1235. (Pubitemid 41345944)
32. McNeel, DG and Malkovsky, M (2005). Immune-based therapies for prostate cancer. Immunol Lett 96: 3-9. (Pubitemid 39600754)
33. Taylor, BS, Varambally, S and Chinnaiyan, AM (2006). Differential proteomic alterations between localised and metastatic prostate cancer. Br J Cancer 95: 425-430. (Pubitemid 44232549)
34. Rhodes, DR, Barrette, TR, Rubin, MA, Ghosh, D and Chinnaiyan, AM (2002). Metaanalysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 62: 4427-4433. (Pubitemid 34827303)
35. Vieweg, J (2007). Immunotherapy for advanced prostate cancer. Rev Urol 9 Suppl 1: S29-S38.
36. Harzstark, AL and Small, EJ (2009). Immunotherapeutics in development for prostate cancer. Oncologist 14: 391-398.
37. Vesalainen, S, Lipponen, P, Talja, M and Syrjänen, K (1994). Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 30A: 1797-1803. (Pubitemid 24377155)
38. Diaz, RM, Galivo, F, Kottke, T, Wongthida, P, Qiao, J, Thompson, J et al. (2007). Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 67: 2840-2848. (Pubitemid 46548974)
39. Finberg, RW, Wang, JP and Kurt-Jones, EA (2007). Toll like receptors and viruses. Rev Med Virol 17: 35-43. (Pubitemid 46114123)
40. Steinhagen, F, Kinjo, T, Bode, C and Klinman, DM (2010). TLR-based immune adjuvants. Vaccine (epub ahead of print).
41. Sfanos, KS, Bruno, TC, Meeker, AK, De Marzo, AM, Isaacs, WB and Drake, CG (2009). Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate 69: 1694-1703.
42. Sfanos, KS, Bruno, TC, Maris, CH, Xu, L, Thoburn, CJ, DeMarzo, AM et al. (2008). Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 14: 3254-3261.
43. Gujar, SA and Michalak, TI (2009). Primary occult hepadnavirus infection induces virus-specific T-cell and aberrant cytokine responses in the absence of antiviral antibody reactivity in the Woodchuck model of hepatitis B virus infection. J Virol 83: 3861-3876.
44. Gujar, SA and Michalak, TI (2005). Flow cytometric quantification of T cell proliferation and division kinetics in woodchuck model of hepatitis B. Immunol Invest 34: 215-236. (Pubitemid 40677459)
45. Ladekarl, M, Agger, R, Fleischer, CC, Hokland, M, Hulgaard, EF, Kirkin, A et al. (2004). Detection of circulating tumor lysate-reactive CD4+ T cells in melanoma patients. Cancer Immunol Immunother 53: 560-566. (Pubitemid 38680263)
46. Betts, MR, Brenchley, JM, Price, DA, De Rosa, SC, Douek, DC, Roederer, M et al. (2003). Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281: 65-78. (Pubitemid 37324571)
47. Porgador, A, Yewdell, JW, Deng, Y, Bennink, JR and Germain, RN (1997). Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6: 715-726. (Pubitemid 27305734)